药物临床试验创新技术研究青年委员会成立大会及第一次学术会议 暨安徽省药监局2020版药物临床试验质量管理规范培训班

2020-11-17 网络 网络

药物临床试验创新技术研究青年委员会成立大会及第一次学术会议 暨安徽省药监局 2020 版药物临床试验质量管理规范培训班在安徽省蚌埠市圆满召开

​由安徽省药监局、中关村玖泰药物临床试验技术创新联盟主办,蚌埠医学院第一附属医院承办的“安徽省药监局2020 版药物临床试验质量管理规范培训班暨药物临床试验创新技术研究青年委员会成立大会及第一次学术会议”于11月7日至11月8日在“珠城”蚌埠顺利召开,来自全国28个省份的1000余名代表参加本次大会。

安徽省药品监督管理局党总书记、局长吴丽华,中关村玖泰药物临床试验技术创新联盟曹彩秘书长,安徽省药监局许可注册处陈咏梅处长,蚌埠医学院党委常委、一附院党委书记金世洋,蚌医药学院党委书记于伟荣、院长刘浩教授,蚌医公共基础学院院长方强、蚌医一附院纪委书记王群出席开幕式,开幕式由蚌医临床医学院院长、一附院副院长高涌教授主持。

蚌医一附院党委书记金世洋同志致辞,首先金书记对大会的成立表示祝贺,对各位的到来表示欢迎,表示在青委会主委周焕教授的带领下,该院机构坚持走专业化发展道路、坚持改革创新、坚持高质量发展,在研究型病房、创新药早期临床研究、仿制药一致性评价、C14放射性同位素标记物质平衡临床试验、葡萄糖钳夹临床试验多项临床试验取得显著成效,为新药创制和仿制药研发提供有力支撑。

曹彩秘书长致辞中,对青委会主委周焕教授的开创性工作给予充分肯定,对省药监局的大力支持表示衷心感谢,提出深入研究、支撑产业、推动行业发展三大任务,青年学者们踏实研究为先、为重才能向国家提交“十四五”满意答卷。

吴丽华局长表示,紧跟党中央国务院指示,加大科技攻关力度,结合科技力量,大力发展生物医药产业,鼓励医疗机构开展药物临床试验,近年来以蚌医一附院为代表的安徽机构取得跨越式发展,有力推动了创新药物研发。下一步省局将加强对药物临床机构日常监管和培训。此次学术会议和GCP培训班将为青年人才搭建交流平台,有利于提升全省GCP水平。

蚌医一附院党委书记金世洋同志致辞

中关村玖泰药物临床试验技术创新联盟曹彩秘书长致辞

安徽省药品监督管理局党总书记、局长吴丽华讲话

本次大会邀请北京大学人民医院方翼教授、首都医科大学附属北京世纪坛医院王兴河教授、浙江大学第一医院申屠建中教授、蚌埠医学院第一附属医院周焕教授等19位专家进行学术报告。

青委会主委周焕教授《研究型病房创新实践》

大会讲者:申屠建中、丁黎、谢海棠、王兴河、周焕、谢一鸣、陈桂玲、王洪东、孙鲁宁

大会讲者:方翼、陈霞、郑姣、贾建国、董文靓

大会讲者:李洪涛、金冬来、张铁强、田之新、董立厚

北京协和医院郑昕教授、上海交通大学医学院附属第九人民医院金剑教授及多位药企研发人员在内的29位论坛嘉宾,就临床试验相关行业热点进行现场讨论。

论坛嘉宾现场讨论

论坛嘉宾现场讨论

论坛嘉宾现场讨论

论坛嘉宾现场讨论

首都医科大学附属北京同仁医院卢来春教授、华西医院国家药物试验机构/临床药理研究所主任王永生教授等26位专家莅临现场,担纲主持。

大会主持人:卢来春、王永生、李晓晖(湘雅)、胡伟、吴建才、段丽莎、王继年、王法财、彭真、沈杰、高丽星、周焕、马涛、宣玲、周颖、丁珏芳

大会主持人:范华莹、赵飞、贺宝霞、万巍、王哲渊;张娟、梅和坤、武晓捷、甘园、王义雷

大会既有行业顶尖专家的高端报告,又有新一代领军人物的创新实践,更给广大青年GCP专家提供了展示的舞台,收到了广泛好评,现场气氛热烈,与会代表纷纷表示本次学术论坛和培训班,干货满满,收获颇丰。

 

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1978238, encodeId=28d219e823832, content=<a href='/topic/show?id=1111e60615a' target=_blank style='color:#2F92EE;'>#管理规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76061, encryptionId=1111e60615a, topicName=管理规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Dec 29 23:57:35 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724755, encodeId=0d771e2475542, content=<a href='/topic/show?id=84c5458013c' target=_blank style='color:#2F92EE;'>#安徽省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45801, encryptionId=84c5458013c, topicName=安徽省)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=894533672038, createdName=charl1234578, createdTime=Wed Aug 18 01:57:35 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904712, encodeId=1a141904e12a3, content=<a href='/topic/show?id=85fa455346c' target=_blank style='color:#2F92EE;'>#学术会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45534, encryptionId=85fa455346c, topicName=学术会议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Oct 07 12:57:35 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950691, encodeId=705f1950691bf, content=<a href='/topic/show?id=e5bf9241085' target=_blank style='color:#2F92EE;'>#质量管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92410, encryptionId=e5bf9241085, topicName=质量管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Mar 12 21:57:35 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032352, encodeId=de3c2032352e4, content=<a href='/topic/show?id=827b92411cc' target=_blank style='color:#2F92EE;'>#质量管理规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92411, encryptionId=827b92411cc, topicName=质量管理规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Wed Jul 28 20:57:35 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903857, encodeId=0af0190385e46, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue May 18 07:57:35 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285952, encodeId=f29e12859525b, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301726, encodeId=b1cb1301e265a, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480943, encodeId=1416148094314, content=<a href='/topic/show?id=96a08e64833' target=_blank style='color:#2F92EE;'>#药物临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87648, encryptionId=96a08e64833, topicName=药物临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65ed7724096, createdName=1508842480_96220439, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1978238, encodeId=28d219e823832, content=<a href='/topic/show?id=1111e60615a' target=_blank style='color:#2F92EE;'>#管理规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76061, encryptionId=1111e60615a, topicName=管理规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Dec 29 23:57:35 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724755, encodeId=0d771e2475542, content=<a href='/topic/show?id=84c5458013c' target=_blank style='color:#2F92EE;'>#安徽省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45801, encryptionId=84c5458013c, topicName=安徽省)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=894533672038, createdName=charl1234578, createdTime=Wed Aug 18 01:57:35 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904712, encodeId=1a141904e12a3, content=<a href='/topic/show?id=85fa455346c' target=_blank style='color:#2F92EE;'>#学术会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45534, encryptionId=85fa455346c, topicName=学术会议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Oct 07 12:57:35 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950691, encodeId=705f1950691bf, content=<a href='/topic/show?id=e5bf9241085' target=_blank style='color:#2F92EE;'>#质量管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92410, encryptionId=e5bf9241085, topicName=质量管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Mar 12 21:57:35 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032352, encodeId=de3c2032352e4, content=<a href='/topic/show?id=827b92411cc' target=_blank style='color:#2F92EE;'>#质量管理规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92411, encryptionId=827b92411cc, topicName=质量管理规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Wed Jul 28 20:57:35 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903857, encodeId=0af0190385e46, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue May 18 07:57:35 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285952, encodeId=f29e12859525b, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301726, encodeId=b1cb1301e265a, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480943, encodeId=1416148094314, content=<a href='/topic/show?id=96a08e64833' target=_blank style='color:#2F92EE;'>#药物临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87648, encryptionId=96a08e64833, topicName=药物临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65ed7724096, createdName=1508842480_96220439, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1978238, encodeId=28d219e823832, content=<a href='/topic/show?id=1111e60615a' target=_blank style='color:#2F92EE;'>#管理规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76061, encryptionId=1111e60615a, topicName=管理规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Dec 29 23:57:35 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724755, encodeId=0d771e2475542, content=<a href='/topic/show?id=84c5458013c' target=_blank style='color:#2F92EE;'>#安徽省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45801, encryptionId=84c5458013c, topicName=安徽省)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=894533672038, createdName=charl1234578, createdTime=Wed Aug 18 01:57:35 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904712, encodeId=1a141904e12a3, content=<a href='/topic/show?id=85fa455346c' target=_blank style='color:#2F92EE;'>#学术会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45534, encryptionId=85fa455346c, topicName=学术会议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Oct 07 12:57:35 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950691, encodeId=705f1950691bf, content=<a href='/topic/show?id=e5bf9241085' target=_blank style='color:#2F92EE;'>#质量管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92410, encryptionId=e5bf9241085, topicName=质量管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Mar 12 21:57:35 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032352, encodeId=de3c2032352e4, content=<a href='/topic/show?id=827b92411cc' target=_blank style='color:#2F92EE;'>#质量管理规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92411, encryptionId=827b92411cc, topicName=质量管理规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Wed Jul 28 20:57:35 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903857, encodeId=0af0190385e46, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue May 18 07:57:35 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285952, encodeId=f29e12859525b, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301726, encodeId=b1cb1301e265a, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480943, encodeId=1416148094314, content=<a href='/topic/show?id=96a08e64833' target=_blank style='color:#2F92EE;'>#药物临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87648, encryptionId=96a08e64833, topicName=药物临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65ed7724096, createdName=1508842480_96220439, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1978238, encodeId=28d219e823832, content=<a href='/topic/show?id=1111e60615a' target=_blank style='color:#2F92EE;'>#管理规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76061, encryptionId=1111e60615a, topicName=管理规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Dec 29 23:57:35 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724755, encodeId=0d771e2475542, content=<a href='/topic/show?id=84c5458013c' target=_blank style='color:#2F92EE;'>#安徽省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45801, encryptionId=84c5458013c, topicName=安徽省)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=894533672038, createdName=charl1234578, createdTime=Wed Aug 18 01:57:35 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904712, encodeId=1a141904e12a3, content=<a href='/topic/show?id=85fa455346c' target=_blank style='color:#2F92EE;'>#学术会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45534, encryptionId=85fa455346c, topicName=学术会议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Oct 07 12:57:35 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950691, encodeId=705f1950691bf, content=<a href='/topic/show?id=e5bf9241085' target=_blank style='color:#2F92EE;'>#质量管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92410, encryptionId=e5bf9241085, topicName=质量管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Mar 12 21:57:35 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032352, encodeId=de3c2032352e4, content=<a href='/topic/show?id=827b92411cc' target=_blank style='color:#2F92EE;'>#质量管理规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92411, encryptionId=827b92411cc, topicName=质量管理规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Wed Jul 28 20:57:35 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903857, encodeId=0af0190385e46, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue May 18 07:57:35 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285952, encodeId=f29e12859525b, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301726, encodeId=b1cb1301e265a, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480943, encodeId=1416148094314, content=<a href='/topic/show?id=96a08e64833' target=_blank style='color:#2F92EE;'>#药物临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87648, encryptionId=96a08e64833, topicName=药物临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65ed7724096, createdName=1508842480_96220439, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1978238, encodeId=28d219e823832, content=<a href='/topic/show?id=1111e60615a' target=_blank style='color:#2F92EE;'>#管理规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76061, encryptionId=1111e60615a, topicName=管理规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Dec 29 23:57:35 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724755, encodeId=0d771e2475542, content=<a href='/topic/show?id=84c5458013c' target=_blank style='color:#2F92EE;'>#安徽省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45801, encryptionId=84c5458013c, topicName=安徽省)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=894533672038, createdName=charl1234578, createdTime=Wed Aug 18 01:57:35 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904712, encodeId=1a141904e12a3, content=<a href='/topic/show?id=85fa455346c' target=_blank style='color:#2F92EE;'>#学术会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45534, encryptionId=85fa455346c, topicName=学术会议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Oct 07 12:57:35 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950691, encodeId=705f1950691bf, content=<a href='/topic/show?id=e5bf9241085' target=_blank style='color:#2F92EE;'>#质量管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92410, encryptionId=e5bf9241085, topicName=质量管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Mar 12 21:57:35 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032352, encodeId=de3c2032352e4, content=<a href='/topic/show?id=827b92411cc' target=_blank style='color:#2F92EE;'>#质量管理规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92411, encryptionId=827b92411cc, topicName=质量管理规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Wed Jul 28 20:57:35 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903857, encodeId=0af0190385e46, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue May 18 07:57:35 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285952, encodeId=f29e12859525b, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301726, encodeId=b1cb1301e265a, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480943, encodeId=1416148094314, content=<a href='/topic/show?id=96a08e64833' target=_blank style='color:#2F92EE;'>#药物临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87648, encryptionId=96a08e64833, topicName=药物临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65ed7724096, createdName=1508842480_96220439, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1978238, encodeId=28d219e823832, content=<a href='/topic/show?id=1111e60615a' target=_blank style='color:#2F92EE;'>#管理规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76061, encryptionId=1111e60615a, topicName=管理规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Dec 29 23:57:35 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724755, encodeId=0d771e2475542, content=<a href='/topic/show?id=84c5458013c' target=_blank style='color:#2F92EE;'>#安徽省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45801, encryptionId=84c5458013c, topicName=安徽省)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=894533672038, createdName=charl1234578, createdTime=Wed Aug 18 01:57:35 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904712, encodeId=1a141904e12a3, content=<a href='/topic/show?id=85fa455346c' target=_blank style='color:#2F92EE;'>#学术会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45534, encryptionId=85fa455346c, topicName=学术会议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Oct 07 12:57:35 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950691, encodeId=705f1950691bf, content=<a href='/topic/show?id=e5bf9241085' target=_blank style='color:#2F92EE;'>#质量管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92410, encryptionId=e5bf9241085, topicName=质量管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Mar 12 21:57:35 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032352, encodeId=de3c2032352e4, content=<a href='/topic/show?id=827b92411cc' target=_blank style='color:#2F92EE;'>#质量管理规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92411, encryptionId=827b92411cc, topicName=质量管理规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Wed Jul 28 20:57:35 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903857, encodeId=0af0190385e46, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue May 18 07:57:35 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285952, encodeId=f29e12859525b, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301726, encodeId=b1cb1301e265a, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480943, encodeId=1416148094314, content=<a href='/topic/show?id=96a08e64833' target=_blank style='color:#2F92EE;'>#药物临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87648, encryptionId=96a08e64833, topicName=药物临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65ed7724096, createdName=1508842480_96220439, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1978238, encodeId=28d219e823832, content=<a href='/topic/show?id=1111e60615a' target=_blank style='color:#2F92EE;'>#管理规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76061, encryptionId=1111e60615a, topicName=管理规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Dec 29 23:57:35 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724755, encodeId=0d771e2475542, content=<a href='/topic/show?id=84c5458013c' target=_blank style='color:#2F92EE;'>#安徽省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45801, encryptionId=84c5458013c, topicName=安徽省)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=894533672038, createdName=charl1234578, createdTime=Wed Aug 18 01:57:35 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904712, encodeId=1a141904e12a3, content=<a href='/topic/show?id=85fa455346c' target=_blank style='color:#2F92EE;'>#学术会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45534, encryptionId=85fa455346c, topicName=学术会议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Oct 07 12:57:35 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950691, encodeId=705f1950691bf, content=<a href='/topic/show?id=e5bf9241085' target=_blank style='color:#2F92EE;'>#质量管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92410, encryptionId=e5bf9241085, topicName=质量管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Mar 12 21:57:35 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032352, encodeId=de3c2032352e4, content=<a href='/topic/show?id=827b92411cc' target=_blank style='color:#2F92EE;'>#质量管理规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92411, encryptionId=827b92411cc, topicName=质量管理规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Wed Jul 28 20:57:35 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903857, encodeId=0af0190385e46, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue May 18 07:57:35 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285952, encodeId=f29e12859525b, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301726, encodeId=b1cb1301e265a, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480943, encodeId=1416148094314, content=<a href='/topic/show?id=96a08e64833' target=_blank style='color:#2F92EE;'>#药物临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87648, encryptionId=96a08e64833, topicName=药物临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65ed7724096, createdName=1508842480_96220439, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1978238, encodeId=28d219e823832, content=<a href='/topic/show?id=1111e60615a' target=_blank style='color:#2F92EE;'>#管理规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76061, encryptionId=1111e60615a, topicName=管理规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Dec 29 23:57:35 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724755, encodeId=0d771e2475542, content=<a href='/topic/show?id=84c5458013c' target=_blank style='color:#2F92EE;'>#安徽省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45801, encryptionId=84c5458013c, topicName=安徽省)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=894533672038, createdName=charl1234578, createdTime=Wed Aug 18 01:57:35 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904712, encodeId=1a141904e12a3, content=<a href='/topic/show?id=85fa455346c' target=_blank style='color:#2F92EE;'>#学术会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45534, encryptionId=85fa455346c, topicName=学术会议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Oct 07 12:57:35 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950691, encodeId=705f1950691bf, content=<a href='/topic/show?id=e5bf9241085' target=_blank style='color:#2F92EE;'>#质量管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92410, encryptionId=e5bf9241085, topicName=质量管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Mar 12 21:57:35 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032352, encodeId=de3c2032352e4, content=<a href='/topic/show?id=827b92411cc' target=_blank style='color:#2F92EE;'>#质量管理规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92411, encryptionId=827b92411cc, topicName=质量管理规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Wed Jul 28 20:57:35 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903857, encodeId=0af0190385e46, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue May 18 07:57:35 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285952, encodeId=f29e12859525b, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301726, encodeId=b1cb1301e265a, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480943, encodeId=1416148094314, content=<a href='/topic/show?id=96a08e64833' target=_blank style='color:#2F92EE;'>#药物临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87648, encryptionId=96a08e64833, topicName=药物临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65ed7724096, createdName=1508842480_96220439, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
    2020-11-19 xuyu
  9. [GetPortalCommentsPageByObjectIdResponse(id=1978238, encodeId=28d219e823832, content=<a href='/topic/show?id=1111e60615a' target=_blank style='color:#2F92EE;'>#管理规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76061, encryptionId=1111e60615a, topicName=管理规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Dec 29 23:57:35 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724755, encodeId=0d771e2475542, content=<a href='/topic/show?id=84c5458013c' target=_blank style='color:#2F92EE;'>#安徽省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45801, encryptionId=84c5458013c, topicName=安徽省)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=894533672038, createdName=charl1234578, createdTime=Wed Aug 18 01:57:35 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904712, encodeId=1a141904e12a3, content=<a href='/topic/show?id=85fa455346c' target=_blank style='color:#2F92EE;'>#学术会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45534, encryptionId=85fa455346c, topicName=学术会议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Oct 07 12:57:35 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950691, encodeId=705f1950691bf, content=<a href='/topic/show?id=e5bf9241085' target=_blank style='color:#2F92EE;'>#质量管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92410, encryptionId=e5bf9241085, topicName=质量管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Mar 12 21:57:35 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032352, encodeId=de3c2032352e4, content=<a href='/topic/show?id=827b92411cc' target=_blank style='color:#2F92EE;'>#质量管理规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92411, encryptionId=827b92411cc, topicName=质量管理规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Wed Jul 28 20:57:35 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903857, encodeId=0af0190385e46, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue May 18 07:57:35 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285952, encodeId=f29e12859525b, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301726, encodeId=b1cb1301e265a, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480943, encodeId=1416148094314, content=<a href='/topic/show?id=96a08e64833' target=_blank style='color:#2F92EE;'>#药物临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87648, encryptionId=96a08e64833, topicName=药物临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65ed7724096, createdName=1508842480_96220439, createdTime=Thu Nov 19 04:57:35 CST 2020, time=2020-11-19, status=1, ipAttribution=)]